Key Takeaways
- Volume-led recovery, margin inflection begins: Revenue and EBITDA both rose 11% QoQ as MMA, NT and DCB volumes rebounded, while China’s anti-involution policy triggered a 7–10% price lift in the NCB chain within days.
- MMA is the engine, and it is scaling fast: The energy segment delivered robust volumes and operating leverage, capacity is expanding to 360 KT by Q4 FY26, and the company claims global volume leadership with intent to hold it.
- Tariff overhang is clearing, not gone: U.S. tariffs on three of four large export products were absorbed via customer-specific sharing; the recent U.S.-India trade deal and tariff reduction from 50%+ to 18%+ should release margin across the value chain, though PDA utilization recovery will lag.
- The pivot to advanced materials is now capitalised: Zone 4 commissioning begins this quarter, the DCB debottlenecking to 140 KTPA is approved, and two JVs go live in FY27, all built on indigenous process technology that management calls its “last man standing” cost advantage.
- What to watch next quarter: Whether the NCB price lift sticks and spreads to other chains, the pace of Zone 4 commissioning and ramp-up, and closure of the growth partnership conversations that management says have accelerated in the last 4–6 weeks.
Volume Recovery & the Quarter’s Drivers
- MMA volumes led the rebound: U.S. volumes resumed after a period of disruption, driving higher capacity utilisation and operating leverage; the company absorbed part of the tariffs but saw demand return, and expects U.S. volumes to stabilise.
- DCB demand pulled by EV adoption: PDCB, a downstream DCB derivative, is seeing an uptick driven by PPS consumption in electric vehicles, which has increased dramatically and is now a structural demand driver.
- Agrochemical top-line dip is a timing artefact: Bulk shipments to the U.S. skewed the quarterly figure; underlying volumes have been stable, though pricing and margins remain under pressure from Chinese dumping.
- Polymers were mixed: PDCB demand improved on the EV theme, but PDA product chains continued to face volume and pricing pressure due to heavy dependency on the U.S. market.
- Export mix hit a record: Exports constituted about 65% of total revenues, the highest both in percentage and absolute terms; the increase in exports drove higher working capital, causing debt and interest costs to rise marginally.
Suyog Kotecha: "Having indigenous technology developed by our own in-house R&D where we can optimize the cost sheets for each of these products gives us that ability and license and one of the reasons why we have been able to increase volumes and I would say, maintain our market share over the course of last 2 years despite significant pricing pressure from China"
China Anti-Involution & the Pricing Inflection
- The policy shift is real and immediate: China removed the VAT rebate on exports for the NCB chain (PNCB, ONCB and downstream products), and pricing in Indian and global markets rose 7–10% within a few days.
- Management expects this to be a continuous process, not a one-off: The deflationary export pricing seen over the last 2–2.5 years from China is expected to fundamentally correct as the anti-involution strategy plays out across more product chains.
- The breadth of impact is hard to quantify: When asked what proportion of the portfolio could see relief, management deflected, stating it is difficult to find areas where China does not compete and that the entire chemical sector is practically impacted.
- NCB debottlenecking is under active consideration to capture the improved pricing environment, though no approval has been given yet.
Suyog Kotecha: "The only impact where it was immediately visible for us was in NCB chain, right, where pricing went up within a span of a few days by almost 7%-10%."
MMA: Global Leadership, Integration & the Tariff Advantage
- Capacity is scaling to 360 KT by Q4 FY26: Steadfast measures are underway to expand from 290+ KT, and the incremental capacity is expected to be available by the end of this fiscal year.
- The company claims global volume leadership: Management stated it can confidently say it is the global leader in MMA by volumes sold, and it intends to remain so.
- Strategy is shifting from scale to value-chain integration: Over the last 12 months the focus was on reaching globally leading capacity and diversifying geographies (Middle East, Africa, U.S.); going forward the emphasis is on Europe, complementary products and blends, and both backward and forward integration.
- U.S. tariff differential is a structural advantage: Chinese MMA manufacturers face higher tariffs in the U.S. market, creating a differentiating advantage for Aarti in the medium to long term.
- MMA is expected to settle at 30–40% of the portfolio on a 2–3 year outlook, making it the single largest segment.
- Management declined to give a medium-term capacity number when asked for a ballpark figure, calling it too specific to commit to.
Suyog Kotecha: "I think from volumes sold in the market, we can confidently say that we are the global leader, right. And we intend to remain a global leader as far as this product is concerned."
Tariffs, Trade Deals & the U.S. Reset
- Tariff sharing was negotiated customer by customer: Of the four large products exported to the U.S. (MMA, PDCB, MEA, NCB), only MEA was exempted; the rest faced full tariffs, and each product and customer had a different settlement on who absorbed what share.
- The U.S.-India trade deal changes the arithmetic: With tariffs reduced from 50%+ to 18%+, margin will accrue to all players in the value chain, and PDA utilisation, which was depressed because the two largest customers consume it in the U.S., is expected to improve with some lag.
- The India-EU FTA opens a new front: Recently concluded, it is expected to generate large growth opportunities for exports and strategic partnerships in high-end specialty chemicals; management argues that if Aarti can compete against Chinese players dumping in India, it can handle European volumes.
Suyog Kotecha: "I think if we are competing against Chinese players, trying to dump volumes in India, I am sure we can handle European volumes."
Zone 4, JVs & the Advanced Materials Pivot
- Zone 4 commissioning is imminent: Calcium chloride and multipurpose plants are expected to be commissioned within this quarter (Q4 FY26); the remaining process blocks (MPP, Chloro toluene and downstream) will be commissioned in a phased manner through the first three quarters of FY27.
- All Zone 4 projects use in-house indigenous technology, which management frames as the core competitive moat that allows cost-sheet optimisation and a “last man standing” ability to hold market share despite Chinese pricing pressure.
- Two JVs are on track for FY27: The Superform JV (agrochemical, paints and coatings) is expected to commission in Q1 FY27; the RESL JV’s first manufacturing unit commenced construction last quarter and is anticipated to be ready in H1 FY27.
- The Superform JV is an import-substitution play: Both parties are investing ₹150 crore each, with revenue potential of ₹300–400 crore; the product is mostly India-centric and currently supplied largely by China and to some extent Europe.
- DCB capacity is being debottlenecked from 120 to 140 KTPA to capture incremental growth from PPS/EV demand; the project has been formally approved.
- Management declined to guide on Zone 4 asset turns or domestic/export mix, citing revenue linkage to crude and BTX pricing and product-selection variability.
Growth Partnerships & the FY28 Ambition
- Multiple growth partnership conversations are active, and management says events over the last 4–6 weeks (U.S.-India trade deal, India-EU FTA) have accelerated them; the intent is to narrow down and close some partnerships to secure the long-term funnel.
- Interest from global players is for long-term strategic partnership projects, with the trade deals expected to help close conversations in the near future.
- The FY28 EBITDA target is still maintained: Management acknowledged there are bumps but stated that if all initiatives are implemented and there is no major external event, it remains committed to achieving the midterm targets.
- FY27 capex will be significantly lower than the current year’s ~₹1,100 crore, as Zone 4 gets commercialised and no other large projects are in the pipeline.
- The agrochemical segment has potential to reach 20% of the top line, and with Zone 4 commissioning, it could cross that number.
Suyog Kotecha: "There are bumps here and there. But I think by and large, if we are able to implement all of it and if there is no major external event, then we remain committed to achieving our midterm targets."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| MMA capacity expansion | Scale from 290+ KT to ~360 KT | Available by end of Q4 FY26 |
| DCB debottlenecking | Capacity increase from 120 to 140 KTPA | Approved; timeline not specified |
| Zone 4 commissioning (first units) | Calcium chloride and multipurpose plants | Within Q4 FY26 |
| Zone 4 commissioning (remaining blocks) | MPP, Chloro toluene and downstream process blocks | Phased through first 3 quarters of FY27 |
| Superform JV commissioning | Agrochemical, paints and coatings applications | Q1 FY27 |
| RESL JV commissioning | First manufacturing unit | H1 FY27 |
| FY27 capex | Significantly lower than FY26 (~₹1,100 crore) | FY27 |
| MMA portfolio share | Settle at 30–40% of portfolio | 2–3 year outlook |
| FY28 EBITDA target | Maintained, barring major external events | FY28 |
| Growth partnership closures | Narrow down and close some long-term strategic partnerships | Near future, aided by recent trade deals |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹2,492 cr, +11% QoQ driven by volume growth across MMA, NT, DCB |
| EBITDA | ₹323 cr, +11% QoQ |
| EBITDA margin | 13.0% (per an analyst's math) |
| Profit After Tax | ₹133 cr, +25% QoQ |
| Exceptional expense (new labour code) | ₹15 cr, one-time impact; further provisions possible pending government notification |
| Exports share | 65% of total revenues, highest ever in percentage and absolute terms |
| Operating cash flow (9M FY26) | ₹500–600 cr |
| CAPEX guidance FY26 | ₹1,100 cr, revised up from ₹1,000 cr due to incremental MMA, PEDA, DCB projects |
| Zone 4 total CAPEX | ₹1,600–1,800 cr, bulk deployed by year-end; ₹300–400 cr remaining for FY27 |
| MMA capacity | ~290+ KT scaling to ~360 KT by Q4 FY26 |
| DCB capacity | 120 KTPA debottlenecking to 140 KTPA |
| MMA share of US exports | 50–60% of total exports to US |
| PDCB share of US exports | 15–25% of total exports to US |
| NCB chain pricing increase | 7–10% within days following China VAT subsidy removal |
| Agrochemicals revenue share | 17–18% on 9M/full-year basis; 12% in Q3 due to bulk shipment timing |